Clinical trial
Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in…
NCT00313872 · Samsung Medical Center, Other · Completed
Key facts
| NCT number | NCT00313872 |
|---|---|
| Title | Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer |
| Official title | Phase III Randomized Trial of Taxotere/Cisplatin Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer |
| Lead sponsor | Samsung Medical Center, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastric Cancer, Metastases |
| Intervention type | Drug |
| Interventions | DP, FOLFIRI |
| Enrollment | 200 |
| Start date | May 1, 2003 |
| Primary completion | Jun 1, 2009 |
| Completion | Jan 1, 2010 |
| First posted | Apr 12, 2006 |
| Last update posted | Jan 12, 2012 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: